The IAF Leadership Board holds responsibility for the IAF on behalf of the Princess Margaret Cancer Centre and The Princess Margaret Cancer Foundation. Their objective is to support the acceleration of research from the Princess Margaret Centre Research Institute towards commercialization, in order to deliver advanced healthcare.
The IAF Leadership Board core comprises the following members:
CEO and Chairman, Gamida Cell: Dr. Julian Adams (IAF Board Chair)
Granting Board Representative, The Princess Margaret Cancer Foundation: Sean Boyd
Interim Research Director, Princess Margaret Cancer Centre: Mitsu Ikura
Venture Partner at Versant Ventures: Stefan Larson
EVP Science & Research, UHN: Brad Wouters
Technology Development and Commercialization Director, UHN: John Reid
Additional Board members from Industry will participate on a revolving basis based on the expertise required by the proposals.